Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

Tackling neuroinflammation and cholinergic deficit in Alzheimer's disease: Multi-target inhibitors of cholinesterases, cyclooxygenase-2 and 15-lipoxygenase.

AlFadly ED, Elzahhar PA, Tramarin A, Elkazaz S, Shaltout H, Abu-Serie MM, Janockova J, Soukup O, Ghareeb DA, El-Yazbi AF, Rafeh RW, Bakkar NZ, Kobeissy F, Iriepa I, Moraleda I, Saudi MNS, Bartolini M, Belal ASF.

Eur J Med Chem. 2019 Apr 1;167:161-186. doi: 10.1016/j.ejmech.2019.02.012. Epub 2019 Feb 8.

PMID:
30771604
2.

NF-κB inhibition rescues cardiac function by remodeling calcium genes in a Duchenne muscular dystrophy model.

Peterson JM, Wang DJ, Shettigar V, Roof SR, Canan BD, Bakkar N, Shintaku J, Gu JM, Little SC, Ratnam NM, Londhe P, Lu L, Gaw CE, Petrosino JM, Liyanarachchi S, Wang H, Janssen PML, Davis JP, Ziolo MT, Sharma SM, Guttridge DC.

Nat Commun. 2018 Aug 24;9(1):3431. doi: 10.1038/s41467-018-05910-1.

3.

Artificial intelligence in neurodegenerative disease research: use of IBM Watson to identify additional RNA-binding proteins altered in amyotrophic lateral sclerosis.

Bakkar N, Kovalik T, Lorenzini I, Spangler S, Lacoste A, Sponaugle K, Ferrante P, Argentinis E, Sattler R, Bowser R.

Acta Neuropathol. 2018 Feb;135(2):227-247. doi: 10.1007/s00401-017-1785-8. Epub 2017 Nov 13.

4.

ALS Associated Mutations in Matrin 3 Alter Protein-Protein Interactions and Impede mRNA Nuclear Export.

Boehringer A, Garcia-Mansfield K, Singh G, Bakkar N, Pirrotte P, Bowser R.

Sci Rep. 2017 Nov 6;7(1):14529. doi: 10.1038/s41598-017-14924-6.

5.

RBM45 homo-oligomerization mediates association with ALS-linked proteins and stress granules.

Li Y, Collins M, Geiser R, Bakkar N, Riascos D, Bowser R.

Sci Rep. 2015 Sep 22;5:14262. doi: 10.1038/srep14262.

6.

RBM45 Modulates the Antioxidant Response in Amyotrophic Lateral Sclerosis through Interactions with KEAP1.

Bakkar N, Kousari A, Kovalik T, Li Y, Bowser R.

Mol Cell Biol. 2015 Jul;35(14):2385-99. doi: 10.1128/MCB.00087-15. Epub 2015 May 4.

7.

Use of biomarkers in ALS drug development and clinical trials.

Bakkar N, Boehringer A, Bowser R.

Brain Res. 2015 May 14;1607:94-107. doi: 10.1016/j.brainres.2014.10.031. Epub 2014 Oct 24. Review.

8.

miR-29 acts as a decoy in sarcomas to protect the tumor suppressor A20 mRNA from degradation by HuR.

Balkhi MY, Iwenofu OH, Bakkar N, Ladner KJ, Chandler DS, Houghton PJ, London CA, Kraybill W, Perrotti D, Croce CM, Keller C, Guttridge DC.

Sci Signal. 2013 Jul 30;6(286):ra63. doi: 10.1126/scisignal.2004177. Erratum in: Sci Signal. 2013 Sep 10;6(292):er6. Balkhi, Mumtaz Y [corrected to Balkhi, M Y].

9.

Retraction: MyoD-dependent regulation of NF-κB activity couples cell-cycle withdrawal to myogenic differentiation.

Parker MH, von Maltzahn J, Bakkar N, Al-Joubori B, Ishibashi J, Guttridge D, Rudnicki MA.

Skelet Muscle. 2013 Jul 18;3(1):15. doi: 10.1186/2044-5040-3-15. No abstract available.

10.

MyoD-dependent regulation of NF-κB activity couples cell-cycle withdrawal to myogenic differentiation.

Parker MH, von Maltzahn J, Bakkar N, Al-Joubori B, Ishibashi J, Guttridge D, Rudnicki MA.

Skelet Muscle. 2012 May 19;2(1):6. doi: 10.1186/2044-5040-2-6. Retraction in: Skelet Muscle. 2013 Jul 18;3(1):15.

11.

IKKα and alternative NF-κB regulate PGC-1β to promote oxidative muscle metabolism.

Bakkar N, Ladner K, Canan BD, Liyanarachchi S, Bal NC, Pant M, Periasamy M, Li Q, Janssen PM, Guttridge DC.

J Cell Biol. 2012 Feb 20;196(4):497-511. doi: 10.1083/jcb.201108118.

12.

NF-κB signaling in skeletal muscle health and disease.

Peterson JM, Bakkar N, Guttridge DC.

Curr Top Dev Biol. 2011;96:85-119. doi: 10.1016/B978-0-12-385940-2.00004-8. Review.

PMID:
21621068
13.

NF-kappaB signaling: a tale of two pathways in skeletal myogenesis.

Bakkar N, Guttridge DC.

Physiol Rev. 2010 Apr;90(2):495-511. doi: 10.1152/physrev.00040.2009. Review.

14.

NF-kappaB functions in stromal fibroblasts to regulate early postnatal muscle development.

Dahlman JM, Bakkar N, He W, Guttridge DC.

J Biol Chem. 2010 Feb 19;285(8):5479-87. doi: 10.1074/jbc.M109.075606. Epub 2009 Dec 14.

15.

The RelA/p65 subunit of NF-kappaB specifically regulates cyclin D1 protein stability: implications for cell cycle withdrawal and skeletal myogenesis.

Dahlman JM, Wang J, Bakkar N, Guttridge DC.

J Cell Biochem. 2009 Jan 1;106(1):42-51. doi: 10.1002/jcb.21976.

PMID:
19016262
16.

IKK/NF-kappaB regulates skeletal myogenesis via a signaling switch to inhibit differentiation and promote mitochondrial biogenesis.

Bakkar N, Wang J, Ladner KJ, Wang H, Dahlman JM, Carathers M, Acharyya S, Rudnicki MA, Hollenbach AD, Guttridge DC.

J Cell Biol. 2008 Feb 25;180(4):787-802. doi: 10.1083/jcb.200707179.

17.

NF-kappaB regulation of YY1 inhibits skeletal myogenesis through transcriptional silencing of myofibrillar genes.

Wang H, Hertlein E, Bakkar N, Sun H, Acharyya S, Wang J, Carathers M, Davuluri R, Guttridge DC.

Mol Cell Biol. 2007 Jun;27(12):4374-87. Epub 2007 Apr 16.

18.

Interplay of IKK/NF-kappaB signaling in macrophages and myofibers promotes muscle degeneration in Duchenne muscular dystrophy.

Acharyya S, Villalta SA, Bakkar N, Bupha-Intr T, Janssen PM, Carathers M, Li ZW, Beg AA, Ghosh S, Sahenk Z, Weinstein M, Gardner KL, Rafael-Fortney JA, Karin M, Tidball JG, Baldwin AS, Guttridge DC.

J Clin Invest. 2007 Apr;117(4):889-901. Epub 2007 Mar 22.

19.

RelA/p65 regulation of IkappaBbeta.

Hertlein E, Wang J, Ladner KJ, Bakkar N, Guttridge DC.

Mol Cell Biol. 2005 Jun;25(12):4956-68.

20.

Effects of nimodipine on the behavioral sequalae of experimental status epilepticus in prepubescent rats.

Mikati MA, Holmes GL, Werner S, Bakkar N, Carmant L, Liu Z, Stafstrom CE.

Epilepsy Behav. 2004 Apr;5(2):168-74.

PMID:
15123017
21.

Modulating cell cycle: current applications and prospects for future drug development.

Gali-Muhtasib H, Bakkar N.

Curr Cancer Drug Targets. 2002 Dec;2(4):309-36. Review.

PMID:
12470209

Supplemental Content

Loading ...
Support Center